rs12551256 — IL33 IL33 protective asthma variant

Intronic IL33 variant where the G allele is negatively associated with asthma (OR 0.71) in a Brazilian mixed-ancestry cohort; the G allele may dampen IL-33 alarmin output from damaged airway epithelium, reducing ILC2 and mast cell activation and blunting type 2 airway inflammation

See your personal result for IL33

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IL-33 Alarmin Variant — The Intronic Brake on Type 2 Airway Inflammation

Interleukin-3311 Interleukin-33
IL-33 is an alarmin cytokine constitutively expressed in the nuclei of airway epithelial and endothelial cells; when tissue is damaged by allergens, viruses, or mechanical stress, IL-33 is passively released from ruptured cells and triggers immediate type 2 immune activation sits at the very top of the type 2 inflammatory cascade that drives asthma, allergic rhinitis, and atopic sensitization. The IL33 gene on chromosome 9p24.1 is one of the most replicated asthma susceptibility loci in human genetics, and variants at this locus reliably associate with altered IL-33 expression levels in bronchial epithelium, plasma IL-33 protein concentration, and lifetime asthma risk. rs12551256 is an intronic variant within IL33 at GRCh38 chr9:6,231,239. The G allele was negatively associated with asthma in a 1,223-person Brazilian cohort (OR 0.71, P=0.017), suggesting it may sit within or near a regulatory element that modulates IL-33 expression or splicing efficiency.

The Mechanism

After tissue damage, IL-33 is released from the nucleus and binds its receptor complex ST2/IL-1RAcP on mast cells, basophils, and group 2 innate lymphoid cells22 group 2 innate lymphoid cells
ILC2s are innate immune cells that respond to epithelial alarmins (IL-33, IL-25, TSLP) without requiring antigen presentation; they are the dominant early source of IL-5 and IL-13 that drives eosinophilic airway inflammation. Binding activates MyD88→TRAF6→NF-κB and MAPK cascades, causing ILC2s and mast cells to flood the airway with IL-5 (driving eosinophilia), IL-13 (driving mucus and bronchospasm), and IL-9 (driving further mast cell activation). Environmental allergen proteases amplify this loop by cleaving full-length IL-33 into shorter, hyper-potent active forms. Variants that reduce IL-33 output from epithelial cells — whether through altered splicing efficiency, disrupted enhancer elements, or other intronic regulatory effects — blunt this entire cascade upstream of every cytokine downstream of IL-33.

The fine-mapping study at the IL33 locus33 fine-mapping study at the IL33 locus
Aneas et al. Nature Communications 2021; identified a 5 kb enhancer-blocking element within the GWAS-defined 41 kb LD block that loops to the IL33 promoter; risk alleles rs1888909-T and rs992969-A increase bronchial epithelial IL33 mRNA and plasma IL-33 protein established that the IL33 asthma locus is an expression quantitative trait locus (eQTL) in airway epithelium, not in bulk lung tissue — meaning that the locus specifically tunes how much IL-33 is produced in the epithelial cells most exposed to inhaled triggers. rs12551256 at chr9:6,231,239 lies within the gene body of IL33, approximately 16 kb downstream of rs992969, and may mark an independent or correlated regulatory element within this same eQTL region.

The Evidence

The primary evidence for rs12551256 comes from a Brazilian case-control study44 Brazilian case-control study
Queiroz et al., Int J Immunogenet 2017; 1,223 subjects genotyped on Illumina 2.5 Human Omni BeadChip; analyses adjusted for sex, age, helminth infection, and ancestry markers in a mixed European/African admixed population. The G allele was negatively associated with asthma (OR 0.71, 95% CI 0.53–0.94, P=0.017), a ~29% reduction in odds in heterozygotes and a larger expected reduction in GG homozygotes under an additive model. The effect size is modest and has not yet been independently replicated for this specific rsid in other cohorts — hence an evidence level of emerging.

The biological plausibility of a protective intronic variant at the IL33 locus is strongly supported by parallel human genetic evidence. The rare IL33 splice acceptor variant rs146597587-C55 rare IL33 splice acceptor variant rs146597587-C
Zhu et al. PLoS Genet 2017; 103,104 participants for eosinophil analysis; 6,465 asthma cases vs 302,977 controls; rs146597587-C heterozygotes have ~40% lower total IL33 mRNA and a strongly protective effect on asthma risk (OR 0.47) and blood eosinophil counts (β=-0.21 SD, P=2.5×10⁻¹⁶) shows that even partial reduction in IL-33 availability provides robust protection against asthma. The clinical importance of the IL-33 pathway is confirmed by a phase 2 trial of itepekimab66 a phase 2 trial of itepekimab
Wechsler et al. NEJM 2021; itepekimab (anti-IL-33 mAb, 300 mg SC every 2 weeks) vs placebo in moderate-to-severe asthma; loss-of-control events 22% vs 41%, OR 0.42, P=0.02, an anti-IL-33 monoclonal antibody, which achieved a 46% relative reduction in asthma loss-of-control events.

Practical Implications

Carriers of the G allele may have modestly lower IL-33 signalling capacity in their airway epithelium, which could translate to lower type 2 airway inflammation burden over a lifetime of allergen exposure. For carriers of AA (no G copies), the absence of this potential dampening variant — combined with other IL33 risk alleles at nearby positions — is a signal for proactive airway management. Practical steps include monitoring expiratory flow before symptoms develop and identifying specific aeroallergen triggers that activate airway epithelial IL-33 release (house dust mite proteases, cockroach allergens, tobacco smoke).

Interactions

rs12551256 lies within the IL33 gene body, approximately 16 kb downstream of the main asthma GWAS signal rs992969 and in the same genomic region as the cluster of IL33 eQTL variants. The degree of linkage disequilibrium between rs12551256 and nearby risk variants (rs992969, rs1888909) is not fully defined, particularly in non-European populations. In the Brazilian study population, LD patterns reflect the admixed European/African ancestry structure of the cohort.

rs146597587 (IL33 splice acceptor LOF variant) and rs992969 (IL33 upstream regulatory variant increasing IL33 expression) are the best-characterized IL33 variants in the platform. Carriers of rs12551256-GG with concurrent rs992969-GG (low-risk configuration at both loci) would represent the IL33 haplotype with the most consistent evidence for dampened IL-33-driven airway inflammation.

The receptor-side variant rs1420101 (IL1RL1/ST2) shapes how cells respond to whatever IL-33 is secreted — individuals with rs12551256-G (lower IL-33 production) and rs1420101 variants affecting sST2 decoy receptor levels have a dual dampening effect on the IL-33 → ST2 signalling axis.

Genotype Interpretations

What each possible genotype means for this variant.

AA Standard IL-33 Intronic Form Normal

Common form with no G-allele dampening effect; standard IL-33 pathway activation potential

You carry two copies of the A allele at rs12551256, the GRCh38 reference allele. This is the most common genotype globally, present in approximately 35% of the population under Hardy-Weinberg expectations. The A/A genotype lacks the G allele that was associated with reduced asthma odds in the Brazilian cohort study. This does not mean you have elevated asthma risk — it simply means you do not carry the modest intronic dampening variant identified at this position. Your asthma risk profile at the IL33 locus is better characterized by nearby variants rs992969 and rs1888909, which have stronger and more replicated evidence.

AG One Copy Protective Allele Beneficial

One G allele associated with modestly reduced asthma odds in population data

The G allele at rs12551256 sits within an intron of IL33, a gene whose expression level in bronchial epithelial cells is tightly coupled to type 2 airway inflammation and asthma susceptibility. The 41 kb LD block around IL33 contains multiple regulatory elements that tune epithelial IL-33 output. An intronic variant with a protective association is consistent with being tagged by, or directly involved in, a regulatory element that reduces IL-33 expression in response to airway damage. The OR of 0.71 for heterozygotes is biologically plausible given that the rare IL33 splice acceptor variant rs146597587, which reduces IL-33 mRNA by ~40% in heterozygotes, achieves OR 0.47 for asthma — a larger effect from a more disruptive variant. The rs12551256-G effect size sits in between no effect and complete pathway attenuation, consistent with a partial regulatory dampening.

GG Homozygous Protective Allele Beneficial

Two copies of the G allele associated with the strongest IL33 intronic dampening effect on asthma risk at this position

The G allele frequency at rs12551256 shows striking population stratification per 1000 Genomes data: European 45%, East Asian 52%, South Asian 55%, Latino 66%, African 14%. The lower frequency in African populations is notable and may explain why the Brazilian cohort (European and African admixed) showed a moderate protective effect — the G allele frequency difference between asthmatic and non-asthmatic groups in an admixed population partly reflects this population stratification. Independent replication in cohorts with better-powered ancestry-stratified analyses would clarify whether the rs12551256-G effect is uniform across ancestries or concentrated in specific population backgrounds. The biological mechanism — if genuine — would likely involve reduced IL-33 production in damaged airway epithelium, blunting the early ILC2 and mast cell activation that initiates type 2 airway inflammation.